Home › Endometrial Cancer › Massachusetts
Endometrial Cancer clinical trials in Massachusetts
53 studies for Endometrial Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Oct 1, 2026 · NCT06586957Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Massachusetts General Hospital Cancer Center, Boston
- Baystate Medical Center, Springfield
- UMass Memorial Medical Centre, Worcester
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Tufts Medical Center ( Site 6052), Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726ALPINE: Maintenance Letrozole/Abemaciclib
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06366347A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- UMass Memorial Medical Ctr, Worcester
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Women · Updated Aug 31, 2026 · NCT04839614A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07227168A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07383506Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.